Advertisement

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Aug
06
Today In Oncology
Durvalumab Plus Radiation Therapy in Frail Patients With Locally Advanced NSCLC
HRR-Altered Metastatic Prostate Cancer Talazoparib Plus Enzalutamide Improves Progression-Free Survival
HER2-Targeted Regimen Yields High Pathologic Complete Response Rate in Locally Advanced Breast Cancer
When Diagnosis Waits: Lung Cancer, PET Access, and Global Oncology
Phase I Trial Evaluates Allogeneic CD70-Targeted CAR T-Cell Therapy in Advanced Renal Cell Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo